John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

New molecules (excluding JAK-STAT): What interests for patients in the future? Volume 27, supplement 4, Novembre 2020

Tables

Author
CHU Hôtel Dieu, Institut des Maladies de l’Appareil Digestif, Service d’hépato-gastroentérologie, oncologie digestive et assistance nutritionnelle, 1, place A. Ricordeau, 44093 Nantes
* Correspondance

Inflammatory bowel diseases are complex diseases involving multiple pathways of the inflammatory and immune responses variably co-existing in our patients. New therapeutic targets are regularly identified allowing the development of new treatments currently being evaluated. The purpose of this review is to summarize the molecules that have demonstrated their effectiveness in phase II trials in Crohn's disease and ulcerative colitis, and whose phase III trials are underway or recently completed.